Subscribe
Home
Issues
Online First
2024
February 2024 - Vol 17 No 1
2023
December 2023 - Vol 16 No 6
October 2023 - Vol 16 No 5
August 2023 - Vol 16 No 4
June 2023 - Vol 16 No 3
April 2023 - Vol 16 No 2
February 2023 - Vol 16 No 1
Issue Archive
Special Issues
Supplements
Guide to New FDA Approvals
Categories
Conference Correspondent
ESMO 2023 - Small Cell Lung Cancer
ONS 2023 - Multiple Myeloma: Wrap-Up
Web Exclusives
OFS Summit
Breast Cancer-OFS Monthly Minutes
Interview with the Innovators
Drug Updates
Media Library
Videos
Rapid Reactions
Audiocasts
Ask the Experts
Master Class Series
Resources
Quick Quiz
CE
Articles
FDA Panel Recommends Stricter Process for Accelerated Approval of Cancer Drugs
TON - Daily
Christin Melton
The FDA held a public meeting on Tuesday to assess whether stricter criteria are needed when considering oncology drugs for accelerated approval. Measures enacted in 1992 allow the FDA to grant accelerated approval for drugs targeted at unmet needs in cancer based solely on data from single-arm studies and relying on endpoints other than the standard metric of overall survival. At the meeting, experts with the FDA's Oncologic Drugs Advisory Committee (ODAC) criticized the FDA, with Silvana Martino, DO, who directs the Breast Cancer Program at the Angeles Clinic and Research Institute in Santa Monica, California, calling its actions "ignorant."
Gary Lyman, MD, MPH, professor of medicine and director of comparative effectiveness and outcomes research at Duke University School of Medicine and the Duke Comprehensive Cancer Center in Durham, North Carolina, sat on the ODAC panel and discussed the hearing with
The Oncology Nurse-APN/PA.
"The major concern of the ODAC is that accelerated approval has been granted on the basis of a single-arm study in more than half of instances, which limits a full comparative look at efficacy and safety," he explained.
Lyman said relying on such limited evidence might be appropriate in exceptional cases, such as for drugs to treat rare tumors or when a drug has very strong, observable treatment effects, but "the default recommendation is that this conditional approval be based on at least one well-designed randomized, controlled trial [RCT] reporting significant improvement in an outcome measurement likely to convey clinically meaningful benefit." In every case, approval should be "based on the robustness of the results in terms of a strong treatment effect and a very favorable risk-to-benefit ratio," said Lyman.
On the rare occasions when accelerated approval is granted without data from an RCT, Lyman said ODAC recommends that the FDA require the drug's maker to have an RCT underway or imminent. The FDA should review plans for the trial to ensure that its design allows for reliable results, suitable to support licensing approval.
The review of the accelerated approval process was prompted by the FDA's controversial decision in December to withdraw approval of bevacizumab (Avastin) in breast cancer, which Lyman said was the first time the agency had rescinded approval of a drug brought to market under this mechanism. "There are a number of others—including six that we reviewed yesterday—that have not fulfilled their postmarketing requirements and may be vulnerable," he added. The drugs in question include Erbitux by Eli Lilly, Bexxar and Arranon by GlaxoSmithKline, Clolar by Genzyme, Vectibix by Amgen, and Gleevec by Novartis for its indication in gastrointestinal stromal tumors.
At the meeting, the panel questioned manufacturers about their failure to submit requisite follow-up data for these six drugs, but the FDA gave no indication that their approval status is in jeopardy. Most of the manufacturers cited difficulty recruiting enough patients for clinical trials to produce meaningful results as the primary reason for the delays. Amgen's representative told the committee the company was confident it had complied with the FDA requirements.
While most companies that receive accelerated approval for a drug show due diligence in complying with follow-up requirements, Lyman said a few have taken a decade or longer to submit the requested data. "The ODAC members [feel] that plans for more frequent updates—perhaps annually—of studies with outstanding validation or postmarketing requirements would help shorten the time interval to completion and consideration for full approval."
Members of the ODAC panel also voiced concern that the FDA had occasionally granted full approval to a cancer drug without requiring solid data from a RCT. "The ODAC believes that, with few exceptions, such approval should be based on at least two well-done RCTs with consistent or robust results," said Lyman.
Lyman acknowledged that patients with cancer and advocacy groups have complained in the past that strict standards delay access to lifesaving medications. "It will be important that no unnecessary delays occur," he said. If drug companies are pushed to fulfill their post-marketing requirements more promptly, Lyman said he expects it to shorten the time to full approval and decrease how long an ineffective or unsafe drug remains on the market.
Related Items
Guidelines on Screening for Breast, Prostate, and Lung Cancers
By
Christin Melton
Web Exclusives
Conference Correspondent
Managing Hyperglycemia in Patients Receiving Steroid Treatment
By
Christin Melton
TON - August 2011 VOL 4, NO 5
Supportive Care
,
Palliative Care
,
Conference Correspondent
Having Evidence-Based Discussions on CAM
By
Christin Melton
TON - June 2011, Vol 4, No 4
Conference Correspondent
Advanced Practice Nurses Forge New Ground in Radiation Oncology Units
By
Christin Melton
Web Exclusives
Conference Correspondent
Changing the Paradigm of Care for Dying Patients
By
Christin Melton
TON - June 2011, Vol 4, No 4
Conference Correspondent
Genotyping: Looking at the Future of Lung Cancer Care
By
Christin Melton
Web Exclusives
Conference Correspondent
Managing Hyperglycemia in Patients Receiving Steroid Treatment
By
Christin Melton
Web Exclusives
Conference Correspondent
A Review of Investigational Drugs at HOPA
By
Christin Melton
Web Exclusives
Drug Updates
Oncology Nurses Best Positioned to Talk to Patients About Lymphedema
By
Christin Melton
Web Exclusives
Conference Correspondent
Preventing Skeletal-Related Events in Patients
By
Christin Melton
Web Exclusives
Conference Correspondent
View the Latest Issue of TON
Read Issue
Home
Issues
Online First
2024
February 2024 - Vol 17 No 1
2023
December 2023 - Vol 16 No 6
October 2023 - Vol 16 No 5
August 2023 - Vol 16 No 4
June 2023 - Vol 16 No 3
April 2023 - Vol 16 No 2
February 2023 - Vol 16 No 1
Issue Archive
Special Issues
Supplements
Guide to New FDA Approvals
Categories
Conference Correspondent
ESMO 2023 - Small Cell Lung Cancer
ONS 2023 - Multiple Myeloma: Wrap-Up
Web Exclusives
OFS Summit
Breast Cancer-OFS Monthly Minutes
Interview with the Innovators
Drug Updates
Media Library
Videos
Rapid Reactions
Audiocasts
Ask the Experts
Master Class Series
Resources
Quick Quiz
CE
Subscribe Today!
To sign up for our newsletter or print publications, please enter your contact information below.
I'd like to receive:
TON
Print Edition
TON
Weekly e‑Newsletter
-- Please Select --
Afghanistan
Åland Islands
Albania
Algeria
American Samoa
Andorra
Angola
Anguilla
Antarctica
Antigua and Barbuda
Argentina
Armenia
Aruba
Australia
Austria
Azerbaijan
Bahamas
Bahrain
Bangladesh
Barbados
Belarus
Belgium
Belize
Benin
Bermuda
Bhutan
Bolivia, Plurinational State of
Bonaire, Sint Eustatius and Saba
Bosnia and Herzegovina
Botswana
Bouvet Island
Brazil
British Indian Ocean Territory
Brunei Darussalam
Bulgaria
Burkina Faso
Burundi
Cambodia
Cameroon
Canada
Cape Verde
Cayman Islands
Central African Republic
Chad
Chile
China
Christmas Island
Cocos (Keeling) Islands
Colombia
Comoros
Congo
Congo, the Democratic Republic of the
Cook Islands
Costa Rica
Côte d'Ivoire
Croatia
Cuba
Curaçao
Cyprus
Czech Republic
Denmark
Djibouti
Dominica
Dominican Republic
Ecuador
Egypt
El Salvador
Equatorial Guinea
Eritrea
Estonia
Ethiopia
Falkland Islands (Malvinas)
Faroe Islands
Fiji
Finland
France
French Guiana
French Polynesia
French Southern Territories
Gabon
Gambia
Georgia
Germany
Ghana
Gibraltar
Greece
Greenland
Grenada
Guadeloupe
Guam
Guatemala
Guernsey
Guinea
Guinea-Bissau
Guyana
Haiti
Heard Island and McDonald Islands
Holy See (Vatican City State)
Honduras
Hong Kong
Hungary
Iceland
India
Indonesia
Iran, Islamic Republic of
Iraq
Ireland
Isle of Man
Israel
Italy
Jamaica
Japan
Jersey
Jordan
Kazakhstan
Kenya
Kiribati
Korea, Democratic People's Republic of
Korea, Republic of
Kuwait
Kyrgyzstan
Lao People's Democratic Republic
Latvia
Lebanon
Lesotho
Liberia
Libya
Liechtenstein
Lithuania
Luxembourg
Macao
Macedonia, the former Yugoslav Republic of
Madagascar
Malawi
Malaysia
Maldives
Mali
Malta
Marshall Islands
Martinique
Mauritania
Mauritius
Mayotte
Mexico
Micronesia, Federated States of
Moldova, Republic of
Monaco
Mongolia
Montenegro
Montserrat
Morocco
Mozambique
Myanmar
Namibia
Nauru
Nepal
Netherlands
New Caledonia
New Zealand
Nicaragua
Niger
Nigeria
Niue
Norfolk Island
Northern Mariana Islands
Norway
Oman
Pakistan
Palau
Palestinian Territory, Occupied
Panama
Papua New Guinea
Paraguay
Peru
Philippines
Pitcairn
Poland
Portugal
Puerto Rico
Qatar
Réunion
Romania
Russian Federation
Rwanda
Saint Barthélemy
Saint Helena, Ascension and Tristan da Cunha
Saint Kitts and Nevis
Saint Lucia
Saint Martin (French part)
Saint Pierre and Miquelon
Saint Vincent and the Grenadines
Samoa
San Marino
Sao Tome and Principe
Saudi Arabia
Senegal
Serbia
Seychelles
Sierra Leone
Singapore
Sint Maarten (Dutch part)
Slovakia
Slovenia
Solomon Islands
Somalia
South Africa
South Georgia and the South Sandwich Islands
South Sudan
Spain
Sri Lanka
Sudan
Suriname
Svalbard and Jan Mayen
Swaziland
Sweden
Switzerland
Syrian Arab Republic
Taiwan, Province of China
Tajikistan
Tanzania, United Republic of
Thailand
Timor-Leste
Togo
Tokelau
Tonga
Trinidad and Tobago
Tunisia
Turkey
Turkmenistan
Turks and Caicos Islands
Tuvalu
Uganda
Ukraine
United Arab Emirates
United Kingdom
United States
United States Minor Outlying Islands
Uruguay
Uzbekistan
Vanuatu
Venezuela, Bolivarian Republic of
Viet Nam
Virgin Islands, British
Virgin Islands, U.S.
Wallis and Futuna
Western Sahara
Yemen
Zambia
Zimbabwe
I have reviewed and consent to the terms of
TON
's
Privacy Policy
, and
TON
has my permission to retain my information in its database, and to forward pertinent communications to me.
START YOUR SUBSCRIPTION